April 29th 2025
The decision makes pz-cel the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
How can digital therapeutic interventions improve symptoms of atopic dermatitis?
April 13th 2022What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.
Impact of dupilumab on quality of life in kids 6 months to 5 years
April 11th 2022An abstract presented at the Revolutionizing Atopic Dermatitis meeting discussed the impact of treatment with dupilumab on the quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.
FDA grants Priority Review to Dupixent® for kids 6 months to 5 years
February 10th 2022The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.